Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Get Free Report) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 6,541 shares, an increase of 495.7% from the August 15th total of 1,098 shares. Based on an average daily volume of 7,438 shares, the short-interest ratio is currently 0.9 days. Currently, 0.4% of the shares of the stock are sold short.
Fidelity Disruptive Medicine ETF Price Performance
Fidelity Disruptive Medicine ETF stock traded up $0.16 during midday trading on Friday, reaching $31.00. The company had a trading volume of 4,171 shares, compared to its average volume of 10,689. Fidelity Disruptive Medicine ETF has a 12-month low of $23.48 and a 12-month high of $32.89. The company has a market capitalization of $49.60 million, a P/E ratio of 41.33 and a beta of 0.77. The firm’s fifty day simple moving average is $30.18 and its 200-day simple moving average is $27.04.
Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC grew its stake in Fidelity Disruptive Medicine ETF by 95.4% during the 4th quarter. Jane Street Group LLC now owns 91,414 shares of the company’s stock valued at $2,473,000 after acquiring an additional 44,630 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Fidelity Disruptive Medicine ETF in the second quarter valued at $282,000. Vise Technologies Inc. purchased a new stake in Fidelity Disruptive Medicine ETF in the 4th quarter valued at about $234,000. Finally, Virtu Financial LLC purchased a new stake in shares of Fidelity Disruptive Medicine ETF in the 4th quarter valued at approximately $228,000.
Fidelity Disruptive Medicine ETF Company Profile
The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.
See Also
- Five stocks we like better than Fidelity Disruptive Medicine ETF
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Fidelity Disruptive Medicine ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fidelity Disruptive Medicine ETF and related companies with MarketBeat.com's FREE daily email newsletter.
